

Iron-Catalyzed C(sp²)–C(sp³) Cross-Coupling of Chlorobenzenesulfonamides with Alkyl Grignard Reagents: Entry to Alkylated Aromatics

Elwira Bisz,^{,‡} and Michal Szostak^{*,†,‡}*

[‡]Department of Chemistry, Opole University, 48 Oleska Street, Opole 45-052, Poland

[†]Department of Chemistry, Rutgers University, 73 Warren Street, Newark, New Jersey 07102, United
States


**RECEIVED DATE (to be automatically inserted after your manuscript is accepted if required
according to the journal that you are submitting your paper to)**

Corresponding author

ebisz@uni.opole.pl

michal.szostak@rutgers.edu

Abstract



- *biologically-relevant sulfonamide scaffold (sulfa drugs)*
- *the most reactive activating group for Fe-catalyzed cross-coupling*
- *operationally-simple conditions* ■ *challenging alkyl nucleophiles*
- *sustainable iron catalysis* ■ *broad scope* ■ *high selectivity*

Alkylated benzenesulfonamides are compounds of high importance in organic synthesis, including the production of pharmaceuticals, agrochemicals and plasticizers. We report the iron-catalyzed C(sp²)-C(sp³) cross-coupling of chlorobenzosulfonamides with alkyl Grignard reagents under mild and sustainable conditions. Electronically- and sterically-varied benzenesulfonamides as well as challenging alkyl organometallics containing β -hydrogen afford alkylated benzenesulfonamides in high to excellent yields. Sulfonamide represents the most reactive activating group for iron-catalyzed cross-coupling. The process affords alkylated benzenesulfonamides poised for medicinal chemistry applications and traceless reductive cleavage.

The iron-catalyzed cross-coupling has emerged as an increasingly powerful method for organic synthesis.^{1,2} The high interest of the organic community in iron catalysis is driven by the abundance of iron in the Earth's crust leading to a sustained catalyst economy.³ Equally importantly, iron-catalysis allows to execute traditionally challenging cross-coupling disconnections,⁴ including alkylative cross-couplings which are notoriously difficult because of the propensity of alkyl organometallic reagents to undergo β -hydride elimination and homo-coupling.⁵ In recent years, iron-catalyzed cross-couplings have attracted a major attention of researchers in pharmaceutical industry.⁶

Sulfonamides are among the most important molecules in drug discovery.⁷ In particular, the discovery of sulfa drugs have led to the construction of the dominant concepts in modern medicinal chemistry,^{7,8} and resulted in the development of a wide range of antibacterial, hypoglycaemic, diuretic and antihypertensive drugs (Figure 1). In modern drug discovery alkylated benzenesulfonamides are further used as lead molecules for the treatment of cancer, as fatty acid amide hydrolase inhibitors, N-myristoyl transferase inhibitors and calcium-sensing receptor antagonists (Figure 1), among other applications.⁹ Furthermore, alkylated benzenesulfonamides are prevalent in industries beyond drug discovery, including as agrochemical agents and plasticizers.¹⁰ As a consequence of the key importance of sulfonamides in organic chemistry, new methods for the synthesis of sulfonamides continue to have a major impact on organic synthesis and medicinal chemistry.¹¹

Inspired by our interest in amide bonds¹² and iron-catalyzed cross-couplings,¹³ herein, we report the iron-catalyzed $C(sp^2)-C(sp^3)$ cross-coupling of chlorobenzenesulfonamides with alkyl Grignard reagents (Figure 2). The reaction proceeds under exceedingly mild conditions using sustainable iron-catalysis. We demonstrate that a broad range of electronically- and sterically-varied benzosulfonamides as well as challenging alkyl organometallics containing β -hydrogen are compatible with these conditions. Mechanistic studies reveal that sulfonamide acts as one of the most reactive activating groups for iron-catalyzed alkylative cross-coupling with Grignard reagents,^{14,15} which may have implications for the future design of iron-catalyzed cross-coupling methods mediated by O-coordinating

additives. Collectively, the process affords alkylated benzenesulfonamides poised for applications in medicinal chemistry as well as traceless reductive cleavage processes.

Notable features of our findings include: (1) the synthesis of alkylated benzenesulfonamides of medicinal interest that would be difficult to access by other methods, (2) the discovery of sulfonamide as the strongest activating group for iron-catalyzed cross-couplings, (3) the potential for using tertiary sulfonamides as traceless activating groups.




Figure 1. Biologically-active sulfonamides: (a) Classic sulfa drugs (top), and (b) pharmaceutically-active alkylated sulfonamides (bottom).





Figure 2. Iron-catalyzed C(sp²)-C(sp³) cross-coupling of chloro-benzenesulfonamides with alkyl Grignard reagents (this study).

Our studies began with an investigation of the cross-coupling of *N,N*-dimethyl-4-chlorobenzenesulfonamide with *n*-alkyl Grignard reagent containing β -hydrogens (Table 1). An important precedent in the cross-coupling of sterically-hindered sulfonamides should be noted.^{14a,b} In contrast to the amide bond, the nitrogen atom in the sulfonamide grouping tends to be pyramidalized,¹⁶ which in turn may influence the coordination. Furthermore, the weak N–SO₂ bond is prone to reductive cleavage under cross-coupling conditions.¹⁷ Hence, at the outset it was unclear if non-sterically demanding sulfonamides can be used as cross-coupling partners. Since we are focused on developing operationally-practical methods of broad synthetic appeal, we selected rapid addition of organometallic reagent and the use of cheap, readily accessible O-coordinating additives.^{14a,b} As shown, no reaction was observed in the absence of iron (Table 1, entry 1). The reaction was inefficient in the absence of additives (entry 2). Pleasingly, we found that the combined use of iron and NMP (NMP = *N*-methyl-2-pyrrolidone) afforded the coupling product in excellent yield (Table 1, entries 3-6). Importantly, while efficient coupling was observed with as little as 50 mol% of NMP (entry 4), the use of excess of NMP afforded the cleanest reactions. We further note that the use of TMEDA (61% yield) or HMTA (hexamethylenetetramine) (70% yield) under the optimized conditions is less efficient; however, DMI (98%) and DMPU (97%) can be used as NMP replacements in this cross-coupling. NMP was selected for the study to enable comparison with the benchmark method. At present, cross-coupling at lower catalyst loading is less efficient. Ongoing studies in our laboratories are focused on the development of iron-catalyzed cross-couplings at low catalyst loadings. Importantly, under these reaction conditions, the cleavage of SO₂–N bond, or side reactions from the Grignard reagents, including β -hydride elimination and homo-coupling were not observed, indicating a significant activating effect of the sulfonamide moiety.

Having determined that sterically-non-hindered *N,N*-dimethyl-4-chlorobenzenesulfonamide serves as an efficient cross-coupling partner, the substrate scope of this reaction was next explored (Table 2). Pleasingly, the reaction was found to tolerate electronically- and sterically-varied benzosulfonamides as well as challenging alkyl organometallics containing β -hydrogen (Table 2, entries 1-12). Importantly,


sulfonamides with varied steric hindrance at the nitrogen atom are readily tolerated, including NMe₂ (entry 1), NEt₂ (entry 2) and N-*i*Pr₂ (entry 3) with no deleterious effect on the coupling. Furthermore, highly medicinally-relevant N-cyclic sulfonamides are readily tolerated (entry 4). The reaction is also compatible with N-Ar sulfonamides (entry 5), which are used in sulfonamide exchange reactions¹⁸ to increase the diverse modifications of the sulfonamide bond, as well as N-Bn sulfonamides, which are used as synthetic equivalent of secondary sulfonamides after hydrogenolysis¹⁹ (entry 6). Intriguingly, very high efficiency without any modification of the reaction conditions was observed in the cross-coupling of a meta-substituted benzosulfonamide (entry 7), indicating that conjugation with the sulfonamide moiety is not required for the coupling. Furthermore, even the ortho-substituted benzenesulfonamide afforded the desired coupling product, albeit in a modest yield (entry 8). The two latter findings sharply contrast with the cross-coupling of the analogous chloro-benzamides,^{13d} which (1) require extensive optimization for the cross-coupling at the non-conjugated position, (2) are completely unreactive in cross-coupling at the sterically-hindered ortho-position.

The scope of the reaction also encompasses challenging secondary alkyl Grignard reagents, such as cyclohexyl (entry 9) and isopropyl (entry 10). Again, these Grignard reagents afford cross-coupling products using the analogous chloro-benzamides in significantly lower yields,^{13d} showing the superior propensity of sulfonamide as the activating group for cross-coupling. Furthermore, isomerization to *n*-alkyl product, which is the major side reaction using other iron-catalyst systems²⁰ was not observed under these mild conditions. Finally, we were pleased to find that other representative Grignard reagents, such as prone to β -hydride elimination phenethyl Grignard reagent (entry 11) and sensitive dioxolane Grignard (entry 12), which serves as a synthetic carbonyl equivalent are readily tolerated in the cross-coupling. It is worthwhile to note that Grignard addition to the electrophilic sulfonamide bond was not observed in any of the tested examples, attesting to the mild conditions and facility of the coupling. Several of the synthesized products map very well onto the structures of bioactive alkylbenzenesulfonamides.^{8,9} Thus, these reactions should find wide application in the preparation of medicinally-relevant scaffolds.

Table 1. Optimization of Fe-Catalyzed Cross-Coupling^a

Entry	Fe(acac) ₃ (mol%)	Ligand	mol%	Time	Yield (%) ^b
1	-	-	-	10 min	0
2	5	-	-	10 min	75
3	5	NMP	20	10 min	88
4	5	NMP	50	10 min	96
5	5	NMP	200	10 min	>98
6	5	NMP	600	10 min	>98

^a1 (0.50 mmol), Fe(acac)₃ (5 mol%), THF (0.15 M), C₂H₅MgCl (1.20 equiv, 2.0 M, THF), 0 °C, 10 min. RMgCl added dropwise over 1-2 s. ^b Determined by ¹H NMR and/or GC-MS.

Table 2. Iron-Catalyzed C(sp²)–C(sp³) Cross-Coupling of Sulfonamides with Alkyl Grignard Reagents^a

Entry	Substrate	2	Product	Yield (%)
1	<chem>CN(C)S(=O)(=O)c1ccc(Cl)cc1</chem>	2a	<chem>CN(C)S(=O)(=O)c1ccc(CC)cc1</chem>	97
2	<chem>CCN(CC)S(=O)(=O)c1ccc(Cl)cc1</chem>	2b	<chem>CCN(CC)S(=O)(=O)c1ccc(CC)cc1</chem>	96
3	<chem>CC(C)N(CC(C)C)S(=O)(=O)c1ccc(Cl)cc1</chem>	2c	<chem>CC(C)N(CC(C)C)S(=O)(=O)c1ccc(CC)cc1</chem>	97

4		2d		95
5		2e		98
6		2f		97
7		2g		93
8 ^b		2h		50
9 ^c		2i		84
10 ^c		2j		74
11 ^c		2k		83
12 ^d		2l		96


^a**1** (0.50 mmol), Fe(acac)₃ (5 mol%), THF (0.15 M), NMP, RMgX (1.20 equiv, THF), 0 °C, 10 min. ^b15 h, 0 °C. ^c1 h, 0 °C. ^d15 h, 23 °C, RMgX (3.0 equiv). See the Supporting Information for details.

Intermolecular competition experiments were conducted to gain insight into the unique reactivity of benzenesulfonamides in the cross-coupling (Schemes 1-2). Intriguingly, we identified sulfonamide as a significantly more potent activating group than the amide bond (Scheme 1, sulfonamide:amide = 11.5:1).^{13d} The excellent activating profile of sulfonamide was further confirmed in the competition with


the ester bond (Scheme 2, sulfonamide:ester = 2.1:1). Hence, to our knowledge, sulfonamide has been identified as the most activating group for iron-catalyzed cross-couplings,^{1,13d,14} which may find wide application in future studies of iron-catalyzed cross-coupling methods. Future work is focused on mechanistic analysis evaluating broad classes of activating groups in iron-catalyzed cross-coupling.

The utility of the sulfonamide bond is not limited to medicinal chemistry applications. For example, a recent manuscript describes reductive cleavage of *n*-alkylbenzosulfonamides catalyzed by Ni.²¹ Thus, in combination with our facile way of preparing diverse *n*-alkylbenzenesulfonamides by iron-catalysis, this method represents a traceless sulfonamide-based approach to *n*-alkylated aromatics (Scheme 3). Furthermore, owing to the utility of SO₂NR₂ moiety, other methods for manipulation of tertiary sulfonamides are well-established, further enhancing the utility of our method.²²


Scheme 1. Intermolecular Competition Experiments: Amides



Scheme 2. Intermolecular Competition Experiments: Esters



Scheme 3. Sulfonamide as Traceless Activating Group



In conclusion, we have reported the iron-catalyzed $C(sp^2)-C(sp^3)$ cross-coupling of chlorobenzenesulfonamides with alkyl Grignard reagents. The method represents a convenient access to alkylated benzenesulfonamides that are widely used in the synthesis of pharmaceuticals, agrochemicals and plasticizers. A broad range of electronically- and sterically-varied benzenesulfonamides and challenging alkyl organometallics containing β -hydrogen undergo cross-coupling under exceedingly mild reaction conditions that tolerate the presence of an electrophilic sulfonamide moiety in the presence of readily-accessible and cheap Grignard organometallics. Importantly, our study demonstrates that sulfonamide acts as the one of most reactive activating groups for iron-catalyzed alkylative cross-couplings, a class of reactions that is broadly used in pharmaceutical settings. Further, the sulfonamide group is poised for applications as traceless activating group. Studies to facilitate further reaction development using sustainable iron-catalysis are in progress and will be reported in due course.

Experimental Section

General Methods. All compounds reported in the manuscript are commercially available or have been previously described in literature unless indicated otherwise. All experiments involving iron were performed using standard Schlenk techniques under argon or nitrogen atmosphere unless stated otherwise. All sulfonamides have been prepared by standard methods.²³ 1H NMR and ^{13}C NMR data are given for all compounds in the Experimental Section for characterization purposes. 1H NMR, ^{13}C NMR

and HRMS data are reported for all new compounds. All products have been previously reported, unless stated otherwise. Spectroscopic data matched literature values. General methods have been published.^{13a}

General Procedure for Iron-Catalyzed C(sp²)-C(sp³) Cross-Coupling. An oven-dried vial equipped with a stir bar was charged with an sulfonamide substrate (neat, typically, 0.50 mmol, 1.0 equiv) and Fe(acac)₃ (typically, 5 mol%), placed under a positive pressure of argon and subjected to three evacuation/backfilling cycles under vacuum. Tetrahydrofuran (0.15 M) and NMP were sequentially added with vigorous stirring at room temperature, the reaction mixture was cooled to 0 °C, a solution of Grignard reagent (typically, 1.2 equiv) was added dropwise with vigorous stirring and the reaction mixture was stirred for the indicated time at 0 °C. After the indicated time, the reaction mixture was diluted with HCl (1.0 N, 1.0 mL) and Et₂O (1 x 30 mL), the organic layer was extracted with HCl (1.0 N, 2 x 10 mL), dried and concentrated. The sample was analyzed by ¹H NMR (CDCl₃, 400 MHz) and GC-MS to obtain conversion, yield and selectivity using internal standard and comparison with authentic samples. Purification by chromatography on silica gel (EtOAc/hexanes = 1/3) afforded the title product.

General Procedure for Determination of Relative Reactivity. According to the general procedure, an oven-dried vial equipped with a stir bar was charged with two chloride substrates (each 0.50 mmol, 1.0 equiv) and Fe(acac)₃ (5 mol%), placed under a positive pressure of argon and subjected to three evacuation/backfilling cycles under vacuum. Tetrahydrofuran (0.15 M) and NMP (neat, 600 mol%) were sequentially added with vigorous stirring at room temperature, the reaction mixture was cooled to 0 °C, a solution of C₂H₅MgCl (2.0 M in THF, 0.25 mmol, 0.50 equiv) was added dropwise with vigorous stirring and the reaction mixture was stirred for 10 min at 0 °C. Following the standard work-up, the sample was analyzed by ¹H NMR (CDCl₃, 400 MHz) and GC-MS to obtain conversion, yield and selectivity using internal standard and comparison with authentic samples.

Characterization Data for Starting Materials

4-Chloro-*N,N*-dimethylbenzenesulfonamide (1a).²⁴ Yield 95% (2.09 g). White solid. ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, *J* = 8.6 Hz, 2H), 7.53 (d, *J* = 8.6 Hz, 2H), 2.72 (s, 6H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 139.4, 134.1, 129.5, 129.2, 38.9.

4-Chloro-*N,N*-diethylbenzenesulfonamide (1b).²⁵ Yield 97% (2.41 g). Colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, *J* = 8.7 Hz, 2H), 7.48 (d, *J* = 8.6 Hz, 2H), 3.24 (q, *J* = 7.1 Hz, 4H), 1.13 (t, *J* = 7.1 Hz, 6H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 138.9, 138.5, 129.2, 128.3, 42.0, 14.1.

4-Chloro-*N,N*-diisopropylbenzenesulfonamide (1c).^{14a} Yield 88% (2.44 g). White solid. ¹H NMR (400 MHz, CDCl₃) δ 7.80 (d, *J* = 8.8 Hz, 2H), 7.45 (d, *J* = 8.8 Hz, 2H), 3.76-3.65 (m, 2 H), 1.27 (d, *J* = 6.8 Hz, 12H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 141.4, 138.3, 129.2, 128.8, 48.9, 22.1.

1-((4-Chlorophenyl)sulfonyl)pyrrolidine (1d).²⁶ Yield 96% (2.35 g). White solid. ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, *J* = 8.7 Hz, 2H), 7.51 (d, *J* = 8.7 Hz, 2H), 3.24 (ddd, *J* = 6.8, 4.4, 2.7 Hz, 4H), 1.80-1.76 (m, 4H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 139.2, 135.6, 129.5, 129.0, 48.1, 25.4.

4-Chloro-*N*-methyl-*N*-phenylbenzenesulfonamide (1e).²⁷ Yield 97% (2.73 g). White solid. ¹H NMR (400 MHz, CDCl₃) δ 7.45 (q, *J* = 8.8 Hz, 4H), 7.35-7.27 (m, 3H), 7.12-7.07 (m, 2H), 3.18 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 141.3, 139.5, 135.0, 129.4, 129.2, 129.2, 127.8, 126.8, 38.3.

***N*-Benzyl-4-chloro-*N*-methylbenzenesulfonamide (1f).**²⁸ Yield 95% (2.82 g). White solid. ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, *J* = 8.7 Hz, 2H), 7.53 (d, *J* = 8.7 Hz, 2H), 7.37-7.27 (m, 5H), 4.14 (s, 2H), 2.60 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 139.3, 136.0, 135.4, 129.6, 129.0, 128.8, 128.5, 128.2, 54.2, 34.44.

3-Chloro-*N,N*-dimethylbenzenesulfonamide (1g).²⁹ Yield 96% (2.11 g). White solid. ¹H NMR (400 MHz, CDCl₃) δ 7.77 (t, *J* = 1.9 Hz, 1H), 7.69-7.65 (m, 1H), 7.61-7.57 (m, 1H), 7.53-7.48 (m, 1H), 2.74 (s, 6H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 137.5, 135.5, 133.0, 130.5, 127.8, 125.9, 38.0.

2-Chloro-*N,N*-dimethylbenzenesulfonamide (1h).^{11b} Yield 95% (2.09 g). White solid. ¹H NMR (400 MHz, CDCl₃) δ 8.05 (dd, *J* = 7.9 Hz, 1H), 7.56-7.47 (m, 2H), 7.44-7.38 (m, 1H), 2.89 (s, 6H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 136.1, 133.7, 132.2, 127.1, 37.5.

Characterization Data for Cross-Coupling Products

4-Ethyl-*N,N*-dimethylbenzenesulfonamide (Table 2, 2a). *New compound.* Prepared according to the general procedure using 4-chloro-*N,N*-dimethylbenzenesulfonamide (0.50 mmol), Fe(acac)₃ (5 mol%), NMP (600 mol%), THF (0.15 M), and C₂H₅MgCl (2.0 M in THF, 1.20 equiv). The reaction mixture was stirred for 10 min at 0 °C. Yield 97% (103.0 mg). Colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, *J* = 8.4 Hz, 2H), 7.37 (d, *J* = 8.5 Hz, 2H), 2.73 (q, *J* = 7.7 Hz, 2H), 2.69 (s, 6H), 1.27 (t, *J* = 7.6 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 149.6, 132.4, 128.5, 127.9, 38.0, 28.8, 15.2. HRMS (ESI/Q-TOF) *m/z*: [M + Na]⁺ calcd for C₁₀H₁₅NO₂SNa 236.0721 found 236.0724.

***N,N*,4-Triethylbenzenesulfonamide (Table 2, 2b).**²⁵ Prepared according to the general procedure using *N,N*,4-triethylbenzenesulfonamide (0.50 mmol), Fe(acac)₃ (5 mol%), NMP (600 mol%), THF (0.15 M), and C₂H₅MgCl (2.0 M in THF, 1.20 equiv). The reaction mixture was stirred for 10 min at 0 °C. Yield 96% (115.6 mg). Colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, *J* = 8.4 Hz, 2H), 7.31 (d, *J* = 8.5 Hz, 2H), 3.23 (q, *J* = 7.1 Hz, 4H), 2.71 (q, *J* = 7.6 Hz, 2H), 1.25 (t, *J* = 7.6 Hz, 3H), 1.13 (t, *J* = 7.2 Hz, 6H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 149.1, 137.4, 128.5, 127.1, 42.1, 28.8, 15.2, 14.2.

4-Ethyl-*N,N*-diisopropylbenzenesulfonamide (Table 2, 2c). *New compound.* Prepared according to the general procedure using 4-chloro-*N,N*-diisopropylbenzenesulfonamide (0.50 mmol), Fe(acac)₃ (5 mol%), NMP (600 mol%), THF (0.15 M), and C₂H₅MgCl (2.0 M in THF, 1.20 equiv). The reaction mixture was stirred for 10 min at 0 °C. Yield 97% (130.4 mg). White solid. Mp = 63-64 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.77 (d, *J* = 8.3 Hz, 2H), 7.28 (d, *J* = 8.3 Hz, 2H), 3.75-3.64 (m, 2H), 2.70 (q, *J* = 7.6 Hz, 2H), 1.26 (d, *J* = 6.8 Hz, 12H), 1.25 (t, *J* = 7.7 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 148.7, 139.9, 128.3, 127.3, 48.6, 28.8, 22.0, 15.2. HRMS (ESI/Q-TOF) *m/z*: [M + Na]⁺ calcd for C₁₄H₂₃NO₂SNa 292.1347 found 292.1344.

1-((4-Ethylphenyl)sulfonyl)pyrrolidine (Table 2, 2d). *New compound.* Prepared according to the general procedure using 1-((4-chlorophenyl)sulfonyl)pyrrolidine (0.50 mmol), Fe(acac)₃ (5 mol%), NMP (600 mol%), THF (0.15 M), and C₂H₅MgCl (2.0 M in THF, 1.20 equiv). The reaction mixture was stirred for 10 min at 0 °C. Yield 95% (113.8 mg). White solid. Mp = 73-74 °C. ¹H NMR (400 MHz,

CDCl₃) δ 7.74 (d, J = 8.1 Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 3.23 (t, J = 6.6 Hz, 4H), 2.73 (q, J = 7.6 Hz, 2H), 1.75 (t, J = 6.6 Hz, 4H), 1.27 (t, J = 7.6 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 149.5, 134.0, 128.5, 127.7, 47.9, 28.8, 25.2, 15.1. HRMS (ESI/Q-TOF) m/z : [M + Na]⁺ calcd for C₁₂H₁₇NO₂SNa 262.0878 found 262.0876.

4-Ethyl-*N*-methyl-*N*-phenylbenzenesulfonamide (Table 2, 2e). *New compound.* Prepared according to the general procedure using 4-chloro-*N*-methyl-*N*-phenylbenzenesulfonamide (0.50 mmol), Fe(acac)₃ (5 mol%), NMP (600 mol%), THF (0.15 M), and C₂H₅MgCl (2.0 M in THF, 1.20 equiv). The reaction mixture was stirred for 10 min at 0 °C. Yield 98% (134.5 mg). White solid. Mp = 78-79 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.44 (d, J = 8.3 Hz, 2H), 7.32-7.21 (m, 5H), 7.12-7.07 (m, 2H), 3.15 (s, 3H), 2.70 (q, J = 7.6 Hz, 2H), 1.24 (t, J = 7.6 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 149.7, 141.6, 133.6, 128.9, 128.2, 128.0, 127.3, 126.6, 38.1, 28.8, 15.1. HRMS (ESI/Q-TOF) m/z : [M + Na]⁺ calcd for C₁₅H₁₇NO₂SNa 298.0878 found 298.0876.

***N*-Benzyl-4-ethyl-*N*-methylbenzenesulfonamide (Table 2, 2f).** *New compound.* Prepared according to the general procedure using *N*-benzyl-4-chloro-*N*-methylbenzenesulfonamide (0.50 mmol), Fe(acac)₃ (5 mol%), NMP (600 mol%), THF (0.15 M), and C₂H₅MgCl (2.0 M in THF, 1.20 equiv). The reaction mixture was stirred for 10 min at 0 °C. Yield 98% (141.0 mg). White solid. Mp = 71-72 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.75 (d, J = 8.3 Hz, 2H), 7.37 (d, J = 8.2 Hz, 2H), 7.33-7.24 (m, 5H), 4.12 (s, 2H), 2.73 (q, J = 7.6 Hz, 2H), 2.57 (s, 3H), 1.27 (t, J = 7.6 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 149.6, 135.7, 134.4, 128.6, 128.6, 128.4, 127.8, 127.6, 54.1, 34.4, 28.8, 15.1. HRMS (ESI/Q-TOF) m/z : [M + Na]⁺ calcd for C₁₆H₁₉NO₂SNa 312.1034 found 312.1035.

3-Ethyl-*N,N*-dimethylbenzenesulfonamide (Table 2, 2g). *New compound.* Prepared according to the general procedure using 3-chloro-*N,N*-dimethylbenzenesulfonamide (0.50 mmol), Fe(acac)₃ (5 mol%), NMP (600 mol%), THF (0.15 M), and C₂H₅MgCl (2.0 M in THF, 1.20 equiv). The reaction mixture was stirred for 10 min at 0 °C. Yield 93% (99.4 mg). Colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.62-7.57 (m, 2H), 7.49-7.43 (m, 2H), 2.74 (q, J = 7.7 Hz, 2H), 2.71 (s, 6H), 1.27 (t, J = 7.6 Hz, 3H).

$^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 145.6, 135.3, 132.5, 129.1, 127.0, 125.2, 38.1, 28.8, 15.5. HRMS (ESI/Q-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{10}\text{H}_{15}\text{NO}_2\text{SNa}$ 236.0721 found 236.0720.

2-Ethyl-*N,N*-dimethylbenzenesulfonamide (Table 2, 2h). *New compound.* Prepared according to the general procedure using 2-chloro-*N,N*-dimethylbenzenesulfonamide (0.50 mmol), $\text{Fe}(\text{acac})_3$ (5 mol%), NMP (600 mol%), THF (0.15 M), and $\text{C}_2\text{H}_5\text{MgCl}$ (2.0 M in THF, 1.20 equiv). The reaction mixture was stirred for 15 h at 0 °C. Yield 50% (53.0 mg). Colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.86 (dd, $J = 8.0, 1.3$ Hz, 1H), 7.51 (td, $J = 7.5, 1.4$ Hz, 1H), 7.39 (dd, $J = 7.7, 0.9$ Hz, 1H), 7.31 (td, $J = 7.9, 1.4$ Hz, 1H), 3.04 (q, $J = 7.5$ Hz, 2H), 2.80 (s, 6H), 1.28 (t, $J = 7.5$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 144.4, 135.5, 133.0, 131.3, 130.1, 126.0, 37.2, 26.3, 15.8. HRMS (ESI/Q-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{10}\text{H}_{15}\text{NO}_2\text{SNa}$ 236.0721 found 236.0717.

4-Cyclohexyl-*N,N*-dimethylbenzenesulfonamide (Table 2, 2i). *New compound.* Prepared according to the general procedure using 4-chloro-*N,N*-dimethylbenzenesulfonamide (0.50 mmol), $\text{Fe}(\text{acac})_3$ (5 mol%), NMP (600 mol%), THF (0.15 M), and *c*- $\text{C}_6\text{H}_{11}\text{MgCl}$ (1.0 M in THF, 1.20 equiv). The reaction mixture was stirred for 60 min at 0 °C. Yield 84% (112.4 mg). White solid. Mp = 102-103 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.69 (d, $J = 8.4$ Hz, 2H), 7.37 (d, $J = 8.2$ Hz, 2H), 2.70 (s, 6H), 2.64-2.53 (m, 1H), 1.92-1.82 (m, 4H), 1.81-1.73 (m, 1H), 1.48-1.35 (m, 4H), 1.31-1.21 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 153.4, 132.7, 128.0, 127.6, 44.6, 38.1, 34.2, 26.8, 26.1. HRMS (ESI/Q-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{14}\text{H}_{21}\text{NO}_2\text{SNa}$ 290.1191 found 290.1187.

4-Isopropyl-*N,N*-dimethylbenzenesulfonamide (Table 2, 2j). *New compound.* Prepared according to the general procedure using 4-chloro-*N,N*-dimethylbenzenesulfonamide (0.50 mmol), $\text{Fe}(\text{acac})_3$ (5 mol%), NMP (600 mol%), THF (0.15 M), and *i*-PrMgBr (1.0 M in THF, 1.20 equiv). The reaction mixture was stirred for 60 min at 0 °C. Yield 74% (84.3 mg). Colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.70 (d, $J = 8.4$ Hz, 2H), 7.39 (d, $J = 8.3$ Hz, 2H), 3.05-2.94 (m, 1H), 2.70 (s, 6H), 1.28 (d, $J = 6.9$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 154.2, 132.8, 128.0, 127.2, 38.1, 34.3, 23.8. HRMS (ESI/Q-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{11}\text{H}_{17}\text{NO}_2\text{SNa}$ 250.0878 found 250.0880.

***N,N*-Dimethyl-4-phenethylbenzenesulfonamide (Table 2, 2k).**³⁰ Prepared according to the general procedure using 4-chloro-*N,N*-dimethylbenzenesulfonamide (0.50 mmol), Fe(acac)₃ (5 mol%), NMP (600 mol%), THF (0.15 M), and PhCH₂CH₂MgCl (1.0 M in THF, 1.20 equiv). The reaction mixture was stirred for 60 min at 0 °C. Yield 83% (119.8 mg). White solid. ¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, *J* = 8.3 Hz, 2H), 7.31 (d, *J* = 8.4 Hz, 2H), 7.27 (d, *J* = 7.5 Hz, 2H), 7.23-7.18 (m, 1H), 7.15-7.12 (m, 2H), 3.03-2.97 (m, 2H), 2.96-2.91 (m, 2H), 2.68 (s, 6H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 147.2, 140.9, 132.9, 129.3, 128.6, 128.0, 126.4, 38.1, 37.9, 37.5.

4-(2-(1,3-Dioxan-2-yl)ethyl)-*N,N*-dimethylbenzenesulfonamide (Table 2, 2l). *New compound.* Prepared according to the general procedure using 4-chloro-*N,N*-dimethylbenzenesulfonamide (0.50 mmol), Fe(acac)₃ (5 mol%), NMP (600 mol%), THF (0.15 M), and (2-(1,3-dioxan-2-yl)ethyl)magnesium bromide (0.5 M in THF, 3.00 equiv). The reaction mixture was stirred for 15 h at 23 °C. Yield 96% (143.7 mg). White solid. Mp = 112-113 °C ¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, *J* = 8.3 Hz, 2H), 7.37 (d, *J* = 8.3 Hz, 2H), 4.52 (t, *J* = 5.1 Hz, 1H), 4.12 (dd, *J* = 10.7, 5.0 Hz, 2H), 3.80-3.72 (m, 2H), 2.84-2.78 (m, 2H), 2.70 (s, 6H), 2.15-2.02 (m, 1H), 1.96-1.89 (m, 2H), 1.40-1.33 (m, 1H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 147.4, 132.9, 129.1, 128.0, 101.0, 66.9, 38.0, 36.2, 30.0, 25.8. HRMS (ESI/Q-TOF) *m/z*: [M + Na]⁺ calcd for C₁₄H₂₁NO₄SSNa 322.1089 found 322.1085.

Acknowledgements. We gratefully acknowledge Narodowe Centrum Nauki (grant no. 2014/15/D/ST5/02731), Rutgers University and the NSF (CAREER CHE-1650766) for generous financial support.

Supporting Information Available. ¹H and ¹³C NMR spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Author Information. Corresponding author: ebisz@uni.opole.pl; michal.szostak@rutgers.edu

References

1. For selected reviews on iron-catalysis, see: (a) Fürstner, A.; Martin, R. Advances in Iron Catalyzed Cross Coupling Reactions. *Chem. Lett.* **2005**, *34*, 624-629. (b) Sherry, B. D.; Fürstner, A. The Promise and Challenge of Iron-Catalyzed Cross Coupling. *Acc. Chem. Res.* **2008**, *41*, 1500-1511. (c) Czaplik, W. M.; Mayer, M.; Cvengros, J.; Jacobi von Wangelin, A. Coming of Age: Sustainable Iron-Catalyzed Cross-Coupling Reactions. *ChemSusChem* **2009**, *2*, 396-417. (d) Plietker, B. Iron Catalysis – Fundamentals and Applications. *Top. Organomet. Chem.* **2011**, Vol. 33. (e) Bauer, E. B. Iron Catalysis II. *Top. Organomet. Chem.* **2015**, Vol. 50. (f) Marek, I.; Rappoport, Z. *The Chemistry of Organoiron Compounds*; Wiley: Weinheim, 2014. (g) Bauer, I.; Knölker, H. J. Iron Catalysis in Organic Synthesis. *Chem. Rev.* **2015**, *115*, 3170-3387. For a review on iron catalysis in natural product synthesis, see: (h) Legros, J.; Fidegarde, B. Iron-promoted C-C bond formation in the total synthesis of natural products and drugs. *Nat. Prod. Rep.* **2015**, *32*, 1541-1555. For a review on iron-catalyzed cross-couplings of C–O electrophiles, see: (i) Bisz, E.; Szostak, M. Iron-Catalyzed C-O Bond Activation: Opportunity for Sustainable Catalysis. *ChemSusChem* **2017**, *10*, 3964-3981.
2. For a leading perspective on homogeneous iron catalysis, see: Fürstner, A. Iron Catalysis in Organic Synthesis: A Critical Assessment of What It Takes To Make This Base Metal a Multitasking Champion. *ACS Cent. Sci.* **2016**, *2*, 778-789.
3. (a) Fürstner, A. Base-Metal Catalysis Marries Utilitarian Aspects with Academic Fascination. *Adv. Synth. Catal.* **2016**, *358*, 2362-2362. (b) Ludwig, J. R.; Schindler, C. S. Catalyst: Sustainable Catalysis. *Chem* **2017**, *2*, 313-316.
4. (a) *Science of Synthesis: Cross-Coupling and Heck-Type Reactions*, Molander, G. A.; Wolfe, J. P.; Larhed, M., Eds.; Thieme: Stuttgart, 2013. (b) *Metal-Catalyzed Cross-Coupling Reactions and More*, de Meijere, A.; Bräse, S.; Oestreich, M., Eds.; Wiley: New York, 2014. (c) *New Trends in Cross-Coupling*; Colacot, T. J., Ed.; The Royal Society of Chemistry: Cambridge, 2015.

5. (a) Jana, R.; Pathak, T. P.; Sigman, M. S. Advances in Transition Metal (Pd,Ni,Fe)-Catalyzed Cross-Coupling Reactions Using Alkyl-organometallics as Reaction Partners. *Chem. Rev.* **2011**, *111*, 1417-1492. (b) Giri, R.; Thapa, S.; Kafle, A. Palladium- Catalysed, Directed C-H Coupling with Organometallics. *Adv. Synth. Catal.* **2014**, *356*, 1395-1411.
6. Piontek, A.; Bisz, E.; Szostak, M. Iron-Catalyzed Cross-Coupling in the Synthesis of Pharmaceuticals: In Pursuit of Sustainability. *Angew. Chem. Int. Ed.* **2018**, *57*, 11116-11128.
7. Drews, J. Drug Discovery: A Historical Perspective. *Science* **2000**, *287*, 1960-1964.
8. Lemke, T. L.; Williams, D. A. *Foye's Principles of Medicinal Chemistry*; Lippincott: Baltimore, 2007.
9. (a) Devendar, P.; Yang, G. F. Sulfur-Containing Agrochemicals. *Top. Curr. Chem.* **2017**, *375*, 82, pp. 1-44. (b) Wypych, G. *Handbook of Plasticizers*; ChemTec Publishing: Toronto, 2012.
10. (a) Fletcher, S.; Lanning, M.; Chen, L. Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof. WO2017011323, Jan 19, 2017. (b) Ishii, T.; Sugane, T.; Kakefuda, A.; Takahashi, T.; Kanayama, T.; Sato, K.; Kuriwaki, I.; Kitada, C.; Suzuki, J. Preparation of piperazine-1-carboxamide and piperidine-1-carboxamide derivatives as inhibitors of fatty acid amide hydrolase (FAAH). WO2008023720, Feb 28, 2008. (c) Brand, S.; Wyatt, P. Preparation of N-myristoyl transferase inhibitors. WO2010026365, Mar 11, 2010. (d) Ogawa, M.; Kitagawa, K.; Shirahashi, H.; Kuribayashi, S. Preparation of N-(3-amino-2-hydroxypropyl)benzenesulfonamide and N-(3-amino-2-hydroxypropyl)thiophenesulfonamide derivatives as calcium-sensing antagonists. WO2009148052, Dec 10, 2009.
11. (a) Chen, Y.; Murray, P. R. D.; Davies, A. T.; Willis, M. C. Direct Copper-Catalyzed Three-Component Synthesis of Sulfonamides. *J. Am. Chem. Soc.* **2018**, *140*, 8781-8787. (b) Tsai, A. S.; Curto, J. M.; Rocke, B. N.; Dechert-Schmitt, A. M. R.; Ingle, G. K.; Mascitti, V. One-Step Synthesis of Sulfonamides from N-Tosylhydrazones. *Org. Lett.* **2016**, *18*, 508-511. (c) DeBergh, J. R.; Niljianskul, N.; Buchwald, S. L. Synthesis of Aryl Sulfonamides via Palladium-Catalyzed Chlorosulfonylation of Arylboronic Acids. *J. Am. Chem. Soc.* **2013**, *135*, 10638-

10641. (d) Zhou, A.; Rayabarapu, D.; Hanson, P. R. "Click, Click, Cyclize": A DOS Approach to Sultams Utilizing Vinyl Sulfonamide Linchpins. *Org. Lett.* **2009**, *11*, 531-534. (e) Shi, F.; Tse, M. K.; Zhou, S.; Pohl, M. M.; Radnik, J.; Hübner, S.; Jähnisch, K.; Brüner, A.; Beller, M. Green and Efficient Synthesis of Sulfonamides Catalyzed by Nano-Ru/Fe₃O₄. *J. Am. Chem. Soc.* **2009**, *131*, 1775-1779. (f) Caddick, S.; Wilden, J.; Judd, D. B. Direct Synthesis of Sulfonamides and Activated Sulfonate Esters from Sulfonic Acids. *J. Am. Chem. Soc.* **2004**, *126*, 1024-1025.
12. (a) Shi, S.; Nolan, S. P.; Szostak, M. Well-Defined Palladium(II)-NHC (NHC = N-Heterocyclic Carbene) Precatalysts for Cross- Coupling Reactions of Amides and Esters by Selective Acyl CO–X (X = N, O) Cleavage. *Acc. Chem. Res.* **2018**, *51*, 2589-2599. (b) Meng, G.; Szostak M. N-Acyl-Glutarimides: Privileged Scaffolds in Amide N-C Bond Cross-Coupling. *Eur. J. Org. Chem.* **2018**, 20-21, 2352-2365.
13. For selected studies from our group, see: (a) Bisz, E.; Szostak, M. Cyclic Ureas (DMI, DMPU) as Efficient, Sustainable Ligands in Iron-Catalyzed C(sp²)–C(sp³) Coupling of Aryl Chlorides and Tosylates. *Green Chem.* **2017**, *19*, 5361-5366. (b) Bisz, E.; Szostak, M. 2-Methyltetrahydrofuran: A Green Solvent for Iron-Catalyzed Cross-Coupling Reactions. *ChemSusChem* **2018**, *11*, 1290-1294. See, also: (c) Piontek, A.; Szostak, M. Iron-Catalyzed C(sp²)-C(sp³) Cross-Coupling of Alkyl Grignard Reagents with Polyaromatic Tosylates. *Eur. J. Org. Chem.* **2017**, *48*, 7271-7276. (d) Bisz, E.; Szostak, M. Iron-Catalyzed C(sp²)–C(sp³) Cross-Coupling of Chlorobenzamides with Alkyl Grignard Reagents: Development of Catalyst System, Synthetic Scope and Application . *Adv. Synth. Catal.* **2018**, DOI: 10.1002/adsc.201800849.
14. For selected pertinent studies on iron-catalyzed cross-couplings, see: (a) Fürstner, A.; Leitner, A. Iron-Catalyzed Cross-Coupling Reactions of Alkyl-Grignard Reagents with Aryl Chlorides, Tosylates, and Triflates. *Angew. Chem. Int. Ed.* **2002**, *41*, 609-612. (b) Fürstner, A.; Leitner, A.; Mendez, M.; Krause, H. Iron-Catalyzed Cross-Coupling Reactions. *J. Am. Chem. Soc.* **2002**,

124, 13856-13863. (c) Fürstner, A.; Leitner, A. A Catalytic Approach to (R)-(+)-Muscopyridine with Integrated “Self-Clearance”. *Angew. Chem. Int. Ed.* **2003**, *42*, 308-311. (d) Fürstner, A.; De Souza, D.; Parra-Rapado, L.; Jensen, J. T. Catalysis-Based Total Synthesis of Latrunculin B. *Angew. Chem. Int. Ed.* **2003**, *42*, 5358-5360. (e) Czaplik, W. M.; Mayer, M.; Jacobi von Wangelin, A. Domino Iron Catalysis: Direct Aryl-Alkyl Cross-Coupling. *Angew. Chem. Int. Ed.* **2009**, *48*, 607-610. (f) Gülak, S.; Jacobi von Wangelin, A. Chlorostyrenes in Iron-Catalyzed Biaryl Coupling Reactions. *Angew. Chem. Int. Ed.* **2012**, *51*, 1357-1361. (g) Gärtner, D.; Stein, A. L.; Grupe, S.; Arp, J.; Jacobi von Wangelin, A. Iron-Catalyzed Cross-Coupling of Alkenyl Acetates. *Angew. Chem. Int. Ed.* **2015**, *54*, 10545-10549. (h) Kuzmina, O. M.; Steib, A. K.; Markiewicz, J. T.; Flubacher, D.; Knochel, P. Ligand-Accelerated Iron- and Cobalt-Catalyzed Cross-Coupling Reactions between N-Heteroaryl Halides and Aryl Magnesium Reagents. *Angew. Chem. Int. Ed.* **2013**, *52*, 4945-4949.

15. For selected pertinent mechanistic studies, see: (a) Fürstner, A.; Martin, R.; Krause, H.; Seidel, G.; Goddard, R.; Lehmann, C. W. Preparation, Structure, and Reactivity of Nonstabilized Organoiron Compounds. Implications for Iron-Catalyzed Cross Coupling Reactions. *J. Am. Chem. Soc.* **2008**, *130*, 8773-8787. (b) Cassani, C.; Bergonzini, G.; Wallentin, C. J. Active Species and Mechanistic Pathways in Iron-Catalyzed C–C Bond-Forming Cross-Coupling Reactions. *ACS Catal.* **2016**, *6*, 1640-1648. For additional studies, see: (c) Casitas, A.; Krause, H.; Goddard, R.; Fürstner, A. Elementary Steps in Iron Catalysis: Exploring the Links between Iron Alkyl and Iron Olefin Complexes for their Relevance in C–H Activation and C–C Bond Formation. *Angew. Chem. Int. Ed.* **2015**, *54*, 1521-1526. (d) Casitas, A.; Rees, J. A.; Goddard, R.; Bill, E.; DeBeer, D.; Fürstner, A. Two Exceptional Homoleptic Iron(IV) Tetraalkyl Complexes. *Angew. Chem. Int. Ed.* **2017**, *56*, 10108-10113.
16. Paquette, L. A.; Leit, S. M. The First Examples of Bridgehead Bicyclic Sultams. *J. Am. Chem. Soc.* **1999**, *121*, 8126-8127.

17. (a) Shoenebeck, F.; Murphy, J. A.; Zhou, S.; Uenoyama, Y.; Miclo, Y.; Tuttle, T. Reductive Cleavage of Sulfones and Sulfonamides by a Neutral Organic Super-Electron-Donor (S.E.D.) Reagent. *J. Am. Chem. Soc.* **2007**, *129*, 13368-13369. For a pertinent example of C–S cleavage, see: (b) Cho, C. H.; Yun, H. S.; Park, K. Nickel(0)-Catalyzed Cross-Coupling of Alkyl Arenesulfonates with Aryl Grignard Reagents. *J. Org. Chem.* **2003**, *69*, 3017-3025.
18. For a recent example, see: (a) Grimm, J. B.; Katcher, M. H.; Witter, D. J.; Northrup, A. B. A New Strategy for the Synthesis of Benzylic Sulfonamides: Palladium-Catalyzed Arylation and Sulfonamide Metathesis. *J. Org. Chem.* **2007**, *72*, 8135-8138. For an early study, see: (b) Klamann, D.; Hofbauer, G. Transamidation, Rearrangement, and Cleavage of Sulfonamides. *Justus Liebigs Ann. Chem.* **1953**, *581*, 182-197.
19. Wuts, P. G. M.; Greene, T. W. *Greene's Protective Groups in Organic Synthesis*; John Wiley & Sons: Hoboken, 2007.
20. Agrawal, T.; Cook, S. P. Iron-Catalyzed Cross-Coupling Reactions of Alkyl Grignards with Aryl Sulfamates and Tosylates. *Org. Lett.* **2013**, *15*, 96-99.
21. Milburn, R. R.; Snieckus, V. The Tertiary Sulfonamide as a Latent Directed-Metalation Group: Ni(0)-Catalyzed Reductive Cleavage and Cross-Coupling Reactions of Aryl Sulfonamides with Grignard Reagents. *Angew. Chem. Int. Ed.* **2004**, *43*, 888-891.
22. (a) Searles, S.; Nukina, S. Cleavage And Rearrangement Of Sulfonamides. *Chem. Rev.* **1959**, *59*, 1077-1103. (b) Viaud, P.; Coeffard, V.; Thobie-Gautier, C.; Beaudet, I.; Galland, N.; Quintard, J. P.; Le Grogne, E. Electrochemical Cleavage of Sulfonamides: An Efficient and Tunable Strategy to Prevent β -Fragmentation and Epimerization. *Org. Lett.* **2012**, *14*, 942-945. (c) Shohji, N.; Kawaji, T.; Okamoto, S. Ti(O-*i*-Pr)₄/Me₃SiCl/Mg-mediated reductive cleavage of sulfonamides and sulfonates to amines and alcohols. *Org. Lett.* **2011**, *13*, 2626-2629. (d) Ohsawa, T.; Takagaki, T.; Ikehara, F.; Takahashi, Y.; Oishi, T. Reductive Removal of Sulfonyl Groups: Cleavage of Sulfonamides and Sulfonates by Alkali Metal combined with Crown Ether. *Chem. Pharm. Bull.* **1982**, *30*, 3178-3186.

23. Kulka, M. Derivatives of *p*-Chlorobenzenesulfonic Acid. *J. Am. Chem. Soc.* **1950**, *72*, 1215-1218.
24. Huang, X.; Wang, J.; Ni, Z.; Wang, S.; Pan, Y. Copper-mediated S-N formation via an oxygen-activated radical process: a new synthesis method for sulfonamides. *Chem. Commun.* **2014**, *50*, 4582-4584.
25. Lai, J.; Chang, L.; Yuan, G. I₂/TBHP Mediated C–N and C–H Bond Cleavage of Tertiary Amines toward Selective Synthesis of Sulfonamides and β -Arylsulfonyl Enamines: The Solvent Effect on Reaction. *Org. Lett.* **2016**, *18*, 3194-3197.
26. Tang, X.; Huang, L.; Qi, C.; Wu, X.; Wu, W.; Jiang, H. Copper-catalyzed sulfonamide formation from sodium sulfinates and amines. *Chem. Commun.* **2013**, *49*, 6102-6104.
27. Ji, S.; Gortler, L. B.; Waring, A.; Battisti, A. J.; Bank, A.; Closson, W. D.; Wriede, P. A. Cleavage of Sulfonamides with Sodium Naphthalene. *J. Am. Chem. Soc.* **1967**, *89*, 5311- 5312.
28. Jiang, Y.; Wang, Q.; Liang, S.; Hu, L.; Little, R. D.; Zeng, C. Electrochemical Oxidative Amination of Sodium Sulfinates: Synthesis of Sulfonamides Mediated by NH₄I as a Redox Catalyst. *J. Org. Chem.* **2016**, *81*, 4713-4179.
29. Tanaka, T.; Yajima, N.; Kiyoshi, T.; Miura, Y.; Iwama, S. Simple N,N-dimethyl phenylsulfonamides show potent anticonvulsant effect in two standard epilepsy models. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 94-97.
30. Rash, F. H.; Hauser, C. R. Condensations at the *p*-methyl group of N,N-dimethyl-*p*-toluenesulfonamide by means of sodium amide in liquid ammonia. *J. Org. Chem.* **1967**, *32*, 3379-3382.